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Hypoxia-enhanced Blood-Brain Barrier Chip
recapitulates human barrier function and shuttling
of drugs and antibodies
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The high selectivity of the human blood-brain barrier (BBB) restricts delivery of many
pharmaceuticals and therapeutic antibodies to the central nervous system. Here, we describe
an in vitro microﬂuidic organ-on-a-chip BBB model lined by induced pluripotent stem cell-
derived human brain microvascular endothelium interfaced with primary human brain
astrocytes and pericytes that recapitulates the high level of barrier function of the in vivo
human BBB for at least one week in culture. The endothelium expresses high levels of tight
junction proteins and functional efﬂux pumps, and it displays selective transcytosis of pep-
tides and antibodies previously observed in vivo. Increased barrier functionality was
accomplished using a developmentally-inspired induction protocol that includes a period of
differentiation under hypoxic conditions. This enhanced BBB Chip may therefore represent a
new in vitro tool for development and validation of delivery systems that transport drugs and
therapeutic antibodies across the human BBB.
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The human blood-brain barrier (BBB) is a unique andselective physiological barrier that controls transportbetween the blood and the central nervous system (CNS)
to maintain homeostasis for optimal brain function. The BBB is
composed of brain microvascular endothelial cells (BMVECs)
that line the capillaries as well as surrounding extracellular matrix
(ECM), pericytes, and astrocytes, which create a microenviron-
ment that is crucial to BBB function1. The brain microvascular
endothelium differs from that found in peripheral capillaries
based on its complex tight junctions, which restrict paracellular
transit and instead, require that transcytosis be used to transport
molecules from the blood through the endothelium and into the
CNS2. BMVECs also express multiple broad-spectrum efﬂux
pumps on their luminal surface that inhibit uptake of lipophilic
molecules, including many drugs, into the brain3,4. The astrocytes
and pericytes provide signals that are required for differentiation
of the BMVECs5,6, and all three cell types are needed to maintain
BBB integrity in vivo as well as in vitro7,8. The BBB is also of
major clinical relevance because dysfunction of the BBB is
observed in many neurological diseases, and the efﬁcacy of drugs
designed to treat neurological disorders is often limited by their
inability to cross the BBB9. Unfortunately, neither animal models
of the BBB nor in vitro cultures of primary or immortalized
human BMVECs alone effectively mimic the barrier and trans-
porter functions of the BBB observed in humans10–12. Thus, there
is a great need for a human BBB model that could be used to
develop new and more effective CNS-targeting therapeutics and
delivery technologies as well as advance fundamental and trans-
lational research7,8.
Development of human induced pluripotent stem (iPS) cell
technology has enabled differentiation of brain-like microvascular
endothelial cells (iPS-BMVECs) that exhibit many properties of
the human BBB, including well-organized tight junctions,
expression of nutrient transporters and polarized efﬂux trans-
porter activity13,14. The trans-endothelial electrical resistance
(TEER) values exhibited by the permeability barrier generated
by these human iPS-BMVECs reach physiological levels
(~3000–5000Ω·cm2) within 24–48 h when cultured in Transwell
inserts or within a microﬂuidic organ-on-a-chip (Organ Chip)
device15–17, a level that is more than an order of magnitude
higher than TEER values previously reported in other in vitro
human BBB models6,15. However, the usefulness of these iPS-
BMVEC models for studies on targeted delivery to the CNS is
limited because they can only maintain these high TEER levels for
~2 days, and the expression of efﬂux pumps in these iPS-
BMVECs does not fully mimic those of human brain endothe-
lium in vivo18. Here, we describe the development of an enhanced
human BBB model created with microﬂuidic Organ Chip culture
technology19 that contains human iPS-BMVECs interfaced with
primary human pericytes and astrocytes, and that uses a devel-
opmentally inspired differentiation protocol20–22. The resulting
human BBB Chip exhibits physiologically relevant levels of
human BBB function for at least 1 week in vitro, including low
barrier permeability and expression of multiple efﬂux pumps and
transporter functions that are required for analysis of drug and
therapeutic antibody transport.
Results
Developmentally inspired differentiation of brain endothe-
lium. Given that the BBB ﬁrst forms in the developing brain in a
relatively oxygen-poor environment (1–8%) before establishment
of the circulatory system23, and oxygen availability has been
shown to play a vital role in endothelial differentiation from a
variety of stem cell sources20,21, we hypothesized that culturing
iPS cells under similar hypoxic conditions could generate more
highly differentiated BMVECs and potentially stabilize their
phenotype. The published differentiation induction protocol for
creating human BMVECs involves culture of iPS cells on Matrigel
for 3 days in mTeSR1 medium followed by 6 days in DMEM-F12
medium, and then 3 days in endothelial cell medium containing
retinoic acid under normoxic (20% O2) conditions13. Thus, to
explore this possibility, we modiﬁed this method for inducing
differentiation of BMVECs from human iPS cells by shifting the
cultures to hypoxic conditions (5% O2) for the last 9 days of the
induction protocol (Supplementary Figure 1a). Importantly,
we found that exposure to hypoxia during this differentiation
protocol produced signiﬁcant (2–6-fold) increases in the mRNA
levels for the endothelial cell–cell adhesion molecules, VE-
cadherin (vascular endothelial cadherin) and PECAM-1 (plate-
let endothelial cell adhesion molecule, also known as CD31), as
well as the inﬂux transporter GLUT-1 (BBB-speciﬁc glucose
transporter), efﬂux transporter P-gp (permeability glycoprotein),
and VEGF-A (angiogenic vascular endothelial growth factor-A),
relative to control iPS-BMVECs induced under normoxic con-
ditions (Supplementary Figure 1b and Supplementary Table 1).
The increased expression of these endothelial molecules that
play an essential role in CNS neovascularization24,25 conﬁrmed
the successful transition of the iPS cells into a human BMVEC
phenotype.
Canonical Wnt/β-catenin signaling is essential for development
of brain microvessels, and Wnt ligands Wnt7a and Wnt7b have
been implicated in BBB development in vivo16,26. We similarly
found that Wnt7a mRNA levels increased by over 25-fold with
the hypoxic induction protocol compared with normoxic
conditions, while Wnt7b levels remained unchanged (Supple-
mentary Figure 1c and Supplementary Table 2). In addition, past
in vitro and in vivo studies showed that Wnt/β-catenin signaling
pathways interplay with hypoxia-induced factor 1α (HIF1α)
signaling27,28. Indeed, ELISA analysis revealed that HIF1α
protein levels were upregulated by exposure to hypoxia during
the differentiation protocol; however, they decreased when the
differentiation was completed and the cells shifted to normoxic
conditions after seeding on-chip (Supplementary Figure 1d).
Interestingly, we found that we could produce similar results by
exposing the iPS cells to 100 µM cobalt chloride (CoCl2) for the
same 9- day period while under normoxic conditions (Supple-
mentary Figure 1d); CoCl2 has been previously shown to
chemically mimic the effects of hypoxia by stabilizing HIF1α29.
This ﬁnding may obviate the need for specialized gases and
culture chambers for induction of improved BMVEC differentia-
tion in future studies.
Reconstitution of a human BBB on-chip under hypoxia. To
explore whether these hypoxia-induced iPS-BMVECs could be
used to build a human BBB Chip with enhanced functionality,
we used soft lithography to create optically clear, poly(dime-
thylsiloxane) (PDMS), 2-channel, microﬂuidic devices containing
an upper CNS microchannel separated from a parallel vascular
microchannel by a porous (2 µm diameter), polyethylene ter-
ephthalate (PET) membrane coated on both sides with an ECM
composed of collagen type IV and ﬁbronectin (Fig. 1a). A mixture
of primary human brain astrocytes and pericytes (seeding ratio
of 7:3) were then cultured in the astrocyte medium on the PET
membrane in the upper channel under static conditions for 1 h.
Human iPS-BMVECs cultured for 8 days under hypoxic (5% O2)
conditions on Matrigel were removed using Accutase and plated
on the bottom surface of the ECM-coated porous membrane in
the lower channel of the microﬂuidic chip in endothelial medium
with addition of retinoic acid (RA) using similar culture condi-
tions and ﬂow rate. Chips were ﬂipped and incubated for 5 h to
induce adhesion of iPS-BMVECs to the membrane. The BBB
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Chip was cultured for one additional day under hypoxia to
promote endothelial monolayer formation and to acclimate the
cells to the device before being shifted to normoxic conditions
for the remainder of the experiment and before initiating con-
tinuous medium ﬂow (100 µL h−1) (Fig. 1b). We also controlled
ﬂow through the vascular channel to maintain physiological
levels of ﬂuid shear stress (6 dyne cm−2 at 100 µL h−1) and a
blood-like viscosity (3–4 cP; modiﬁed by adding 3.5% dextran to
the medium).
Confocal immunoﬂuorescence microscopic analysis after 3 days
of microﬂuidic culture revealed that these conditions resulted in
formation of an iPS-BMVEC monolayer that covered all four
walls of the lower channel, creating a hollow vascular lumen, in
addition to being interfaced directly across the porous ECM-
coated membrane with primary human pericytes and astrocytes
in the CNS channel above (Fig. 1a, Supplementary Movie 1).
Higher magniﬁcation views revealed that the astrocytes extended
processes through the 2 µm pores of the PET membrane, and
thus, came into direct contact with the luminal surface of the
brain endothelium below (Supplementary Movie 2). These
hypoxia-induced iPS-BMVECs also formed well developed tight
junctions containing ZO-1 and Claudin-5, and expressed high
levels of the cell–cell adhesion protein PECAM-1 along their
lateral borders, as well as GLUT-1 and P-gp transporters on their
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Fig. 1 Reconstitution of the human BBB in an Organ Chip microﬂuidic device. a Photograph (left), schematic illustration (center), and immunoﬂuorescence
micrographs (right) of a 2-channel microﬂuidic Organ Chip with iPS-BMVECs cultured on all surfaces of the basal vascular channel, and primary human
brain astrocytes and pericytes on the upper surface of the central horizontal membrane in the apical parenchymal channel. At the top right, z-stack images
of the pericytes (yellow, F-actin staining) and astrocytes (white, GFAP staining) in the top channel of the BBB Chip are reconstituted and shown from
above; a side view of similar stacked images for the lower vascular channel containing BMVECs (blue, ZO-1 staining) is shown at the bottom right. A video
of overlay z-stack reconstituting this 3D BBB can be seen in Supplementary Movie 1. b Timeline for the in vitro differentiation of the human iPS-BMVECs,
and seeding in the BBB Chips. c Immunoﬂuorescence micrographs of the human brain endothelium cultured on-chip for 3 days labeled with ZO-1, Claudin-
5, PECAM-1, GLUT-1, and P-glycoprotein (bar, 20 µm). d Electron micrographs of the human brain microvascular endothelium after 3 days in the BBB Chip,
highlighting the presence of well-formed tight junctions (top, arrow) and adherens junctions (bottom, arrow) (bar, 100 nm). e Low (left) and high (right)
magniﬁcation immunoﬂuorescence micrographic views of the human brain microvascular endothelium cultured on-chip for 3 days viewed from above
demonstrating high levels of expression of ZO-1 and GLUT-1 across the entire endothelial cell monolayer (bar, 50 µm)
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apical cell membrane (Fig. 1c). Electron microscopic analysis
conﬁrmed that the differentiated iPS-BMVEC monolayer also
displayed well-developed tight junctions and adherens junctions
with characteristic morphology along the membrane–membrane
interfaces between adjacent endothelial cells (Fig. 1d). Under
these ﬂow conditions, the endothelial monolayer within the
human BBB Chip maintained its tight junctional integrity and
continued to express high levels of ZO-1 as well as the glucose
transporter GLUT-1—the major nonneuronal glucose transporter
in brain—on their apical surface for at least 1 week in culture,
as detected by immunoﬂuorescence microscopy (Fig. 1e).
Hypoxia-induced enhancement of brain-speciﬁc endothelial
cell differentiation was also observed when gene and protein
expression levels of representative BBB markers were compared
with iPS-BMVECs cultured on-chip differentiated under hypoxic
versus normoxic conditions. Statistically signiﬁcant increases in
mRNA expression were observed for genes encoding GLUT-1,
insulin receptor protein (INSR), and the BBB efﬂux transport
proteins P-gp, BCRP (breast cancer resistant protein), and
multidrug resistance proteins 1 and 4 (MRP1 and MRP4), as
well as endothelial cell-speciﬁc VE-cadherin (Supplementary
Figure 2a and Supplementary Table 3). Increases in P-gp and
BCRP expression were also conﬁrmed by western blot analysis
(Supplementary Figure 2b and Supplementary Table 3). More-
over, mass spectrometric (MS) analysis of iPS-BMVECs collected
from BBB Chips on the 3rd day of seeding revealed higher protein
levels of ATP-binding cassette (ABC) and solute carrier (SLC)
transporter proteins in hypoxia-differentiated brain endothelium
cultured in the BBB Chips compared with endothelium
differentiated under normoxic conditions (Fig. 2a, Supplementary
Figure 3 and Supplementary Table 4). These results are similar to
those from previous proteomic studies that also demonstrated
enrichment of BCRP1, MRP1, and MRP4 proteins in the BBB
relative to other microvessels in animal studies30. In addition, MS
analysis revealed that the hypoxia-induced iPS-BMVECs deposit
their own basement membrane ECM containing higher levels of
collagen IV, laminin, and perlecan (basement membrane-speciﬁc
heparan sulfate proteoglycan), ﬁbronectin, SPARC, and agrin
compared with when differentiated under normoxic conditions
(Supplementary Table 5); these molecules are also found within
the basement membrane of the human BBB in vivo31. Further-
more, to determine the contribution of astrocytes and pericytes
to the function of iPS-derived human brain microvascular
endothelium, we compared the mRNA proﬁles of iPS-BMVECs
in mono-culture versus co-culture under continuous ﬂow in the
microﬂuidic BBB Chip. The mRNA levels of INSR, VE-cadherin,
MRP1, and ZO-1 were all signiﬁcantly higher in iPS-derived
microvascular endothelium when co-cultured with brain astro-
cytes and pericytes on-chip (Supplementary Figure 4).
Reconstitution of in vivo levels of BBB function on-chip.
Importantly, the higher expression of BMVEC-speciﬁc surface
markers we observed in the presence of pericytes and astrocytes
(Fig. 1, Supplementary Figure 4) was associated with enhanced
barrier function, as quantiﬁed by measuring TEER on-chip using
BBB Chips that contained integrated electrodes32. This method
generates results as impedance in Ohms (Ω) rather than resis-
tance (Ω·cm2) because it is not normalized for surface area. These
studies revealed that the impedance values of BBB Chips created
with iPS-BMVECs differentiated under hypoxic conditions along
with astrocytes and pericytes were ~25,000Ω (Fig. 2b), which is
2 orders of magnitude higher than levels previously reported for
BBB chips containing primary human BMVECs along with the
brain perivascular cells (~400Ω) (Supplementary Figure 5). In
contrast, while chips containing iPS-BMVECs established under
normoxic conditions displayed a similar high maximum
impedance value of ~24,000Ω at 2 days after plating, barrier
levels dropped by more than 50% by day 3, and by >80% at
1 week (Fig. 2b). These latter results were nearly identical to those
previously reported by others who cultured iPS-BMVECs estab-
lished under normoxic conditions in either Transwell inserts or
Organ Chip devices13,33. We independently conﬁrmed these
results using ﬂuorescently labeled dextran tracers to measure
barrier integrity. The apparent permeability (Papp) of the BBB
Chip lined by hypoxia-induced iPS-BMVECs, astrocytes and
pericytes was very low (~10–8–10–9 cm s−1), and the Papp value
inversely correlated with the size of the tracer (average Papp=
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Fig. 2 Physical barrier functions of the human BBB reconstituted on-chip.
a Graph showing protein expression ratios of ABC and SLC transporter
proteins in the iPS-hBMVECs differentiated under hypoxic conditions
relative to normoxic conditions. b Impedance values for the human BBB
measured in the TEER chip over the ﬁrst 7 days of culture on-chip
(recorded in the frequency range of 0.1 Hz–100 kHz) with iPS-BMVECs
that were differentiated under hypoxia (closed circles) or normoxia
(open triangles). c Impedance values for the BBB formed by the same
human astrocytes, pericytes, and iPS-hBMVECs that were differentiated
under hypoxia (closed circles) or normoxia (open triangles) but cultured
in static Transwell inserts measured by TEER measurement machine
(EVOM2). Data are represented as ± SE, N= 3. Statistical analysis is
two-way ANOVA with Tukey’s multiple comparisons test; *P < 0.05;
**P < 0.001; ***P < 0.0001
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~8.9, 1.1, and 0.24 × 10–8 cm s−1 for 3,10, and 70 kDa dextrans,
respectively) (Supplementary Figure 6), as previously demon-
strated in vitro and in vivo34,35. It is important to note that ﬂuid
ﬂow also appeared to be required to sustain barrier function over
time as we did not observe this level of barrier development when
the same hypoxia-induced BMVECs were interfaced with astro-
cytes and pericytes cells in static Transwell cultures (Fig. 2c).
Furthermore, when we treated BBB Chips lined with iPS-
BMVECs differentiated under normoxic conditions with the
HIF1α inducer CoCl2 (100 µM), we produced nearly identical
enhancement of TEER and similar results were obtained with
another chemical hypoxia mimetic, dimethyloxalylglycine
(DMOG; 100 µM) (Supplementary Figure 7). The highly
enhanced, in vivo-like level of barrier function (> 20,000Ω)
obtained with iPS-derived hBMVECs differentiated using CoCl2
also could be prolonged for more than 2 weeks when cultured
under continuous ﬂow in the microﬂuidic BBB Chip (Supple-
mentary Figure 8a). In contrast, this high level of barrier function
again was not obtained when the same cells were interfaced with
astrocytes and pericytes under static conditions in Transwell
cultures (Supplementary Figure 8b). Confocal immunoﬂuores-
cence microscopic analysis of the CoCl2-activated human BBB
Chips also conﬁrmed that high levels of expression of ZO-1 and
GLUT-1 were sustained on the surface of the iPS-BMVECs in
these cultures (Supplementary Figure 9).
An in vitro model to study molecular trafﬁcking across the
BBB. Next, we tested if the enhanced human BBB Chip con-
taining hypoxia-differentiated iPS-BMVECs, astrocytes and
pericytes can recreate a functional metabolic barrier that regulates
molecular trafﬁc across the BBB, and if this occurs in a more
physiologically relevant manner than in chips containing cells
differentiated under normoxic conditions. The array of ABC
transporters in the BBB, which includes P-gp, MRP1 & 4, and
BCRP, provides an important defense mechanism that actively
secretes molecules leaked out of blood back into the capillary
lumen in order to protect the brain36,37. As we found that all of
these ABC efﬂux pumps are expressed on the apical surface of the
human iPS-BMVECs induced by hypoxia (Fig. 1c, Fig. 2a), we
next analyzed their functionality and substrate selectivity. The
hypoxia induction method was used for this and all subsequent
studies because small molecule inducers may not mimic all of the
effects of the hypoxic environment38,39, and thus, their use would
require further system characterization.
To assess P-gp activity in the BBB Chip, we pretreated the
chips with the P-gp inhibitor, verapamil, and then the known P-
gp substrates, rhodamine 123 and DiOC240 as well as the drug
citalopram, were perfused through the endothelium-lined vas-
cular channel of the BBB Chips. Transcytosis of the P-gp
substrate molecules with and without P-gp inhibitor treatment
was measured under the same continuous ﬂow conditions (100
µL h−1), and hence shear stress, in both channels; thus, there was
no difference in the unstirred water layer between the chips.
Transcytosis of the P-gp substrate molecules was also carried out
under static conditions using the BBB Transwell model on the
second day after the cell seeding when the barrier integrities were
similar to the BBB Chip model (3 kDa Dextran Papp values=
~2 × 10–7 cm s−1). The Papp of rhodamine 123 and DiOC2 were
calculated by measuring changes in their ﬂuorescent intensities
between the two channels; MS analysis was used to measure the
permeability of citalopram.
These studied revealed signiﬁcant enhancement of the perme-
ability of all three of these molecules through the BBB on-chip
when the P-gp efﬂux pump was blocked by its inhibitor,
verapamil, whereas a signiﬁcant increase in the permeability of
these molecules could not be detected when the same cells were
interfaced to form a BBB in static Transwell cultures (Fig. 3b).
Remarkably, citalopram was also shown to increase its perme-
ability when P-gp was inhibited in the microﬂuidic BBB Chip
(Fig. 3a), which recapitulates similar in vivo ﬁndings shown in
past animal studies10,41. This is an important result because all
past in vitro BBB models failed to identify citalopram as a P-gp
substrate42,43.
To analyze the activities of BCRP and MRP1 transporter
proteins, the BBB Chips were pretreated with inhibitors of various
ABC transporter inhibitors, including verapamil MK571, and
Ko143 that target P-gp, the MRPs and BCRP, respectively, and
then uptake of ﬂuorescent substrates, rhodamine 123 and DiOC2,
was quantiﬁed under ﬂow using ﬂuorescent dextran (3 kDa) to
monitor barrier integrity. When we measured the Papp of these
two ABC transporter substrates in BBB Chips containing iPS-
BMVECs differentiated under hypoxic conditions along with
astrocytes and pericytes, we found that inhibition of P-gp with
verapamil resulted in signiﬁcant inﬂux of rhodamine 123 and
DiOC2 into the CNS channel, and inhibition of BCRP with
Ko143 had a small but signiﬁcant effect on transport of DiOC2,
but no effect on rhodamine 123, as previously described in other
models13,44 (Fig. 3c). In contrast, when similar studies were
carried out with BBB Chips generated under normoxic condi-
tions, we observed an increase of rhodamine 123 in the CNS
channel when MRP1 was inhibited, but no change when P-gp was
inhibited, and DiOC2 inﬂux was not affected by any of the
inhibitors (Fig. 3c). As P-gp is the main efﬂux pump for
rhodamine 12345,46 and DiOC2 inﬂux was modulated in a
manner similar to what is observed in vivo45 in the hypoxic chips,
these studies demonstrate that while the iPS-BMVECs differ-
entiated under normoxic conditions may generate an effective
permeability barrier13,47, they do not fully recapitulate the human
BBB’s specialized molecular transport functions that are highly
relevant to the drug development process.
To further investigate the potential of the hypoxia-induced
human BBB Chip as an in vitro tool to study brain transporter-
dependent drug efﬂux, we tested the cancer drug doxorubicin
(Dox). While Dox is used to treat many types of cancer, its
efﬁcacy for brain tumors is limited due to poor penetration of the
drug through the BBB because it is pumped back out of the
endothelium and into the blood predominantly by P-gp
transporters48, and less by MRP149 or BCRP50. Consistent with
these in vivo observations in humans, we found that inhibition of
P-gp with Verapamil induced more than a 2.7-fold increase in
Dox inﬂux into the CNS channel (rise in Papp from 1.4 to 3.7 ×
10–8 cm s−1) when added under ﬂow (100 µL h−1) through the
vascular channel of the BBB Chip (Fig. 3c), which is similar to the
P-gp efﬂux ratio observed in vivo37. Again, as observed in vivo,
inhibition of MRP1 or BCRP did not alter the permeation of Dox
into the CNS channel (Fig. 3c). Together, these results suggest
that differentiation of iPS-BMVECs in the presence of hypoxia,
and positioning of these cells under physiological ﬂow at a tissue-
tissue interface with human brain pericytes and astrocytes,
generates of an artiﬁcial human BBB that exhibits higher
substrate speciﬁcity and functionality of the efﬂux barrier than
previously reported in any in vitro BBB model.
Reversible osmotic opening of the human BBB on-chip.
Hyperosmolar agents, such as high concentration mannitol
solutions, are used clinically to overcome the BBB permeability
limitation in order to increase delivery of drugs to the brain51,52.
Intravenous infusion of a mannitol solution induces reversible
opening of pores within the BBB with a radius of about 200 Å in
animals53 and humans53,54, and this recovers due to bulk ﬂuid
ﬂow from the blood to the brain54. We therefore explored whe-
ther we can use our hypoxia-enhanced BBB Chip to model
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delivery of large antibodies, such as those used as cancer ther-
apeutics, by opening the barrier with hypertonic mannitol on-
chip. Hypertonic (485 mOsmol L−1) mannitol solution was ﬂo-
wed through the endothelium-lined vascular channel of the BBB
Chip for 1 h to open the BBB, and then additional hypertonic
medium containing 10 kDa dextran and the anti-cancer ther-
apeutic antibody, cetuximab, was ﬂowed for an additional hour
through the same channel (Fig. 4a).
Constant exposure to the hypertonic medium resulted in a 50%
drop in TEER within 2 h, which gradually recovered to normal
levels within 4 h following infusion of isotonic medium into the
vascular channel (Fig. 4b). Osmotic opening of the BBB in this
manner also resulted in increased penetration of both 10 kDa
dextran (Fig. 4c) and the cetuximab antibody (Fig. 4d) into the
CNS channel, as measured by a rise in Papp from 3 to 32 × 10–8
cm s−1 and from 2 to 5.1 × 10–8 cm s−1, respectively. The
hypertonic medium was replaced by isotonic medium containing
the same compounds after 1 h to allow the BBB Chip to recover
barrier function, and after an additional 30 min, we found that
the barrier integrity measured by TEER had not fully recovered
(Fig. 4b), indicating that both the dextran and the antibody
continued to penetrate through the BBB and into the CNS
channel. However, the permeabilities of dextran (Fig. 4c) and the
antibody (Fig. 4d) decreased to the normal range within 4 h,
resulting in full recovery of barrier integrity (Fig. 4b). To our
knowledge, this is the ﬁrst demonstration of delivery of a
clinically approved antibody drug by reversible osmotic opening
of the human BBB in vitro, which mimics responses seen in
human patients52,54.
Recapitulation of BBB-shuttling activities on-chip. The BBB
prevents the transport of nearly 100% of large drugs (> 500 Da)
and antibodies (150 kDa) into the brain, and thus, many
laboratories are seeking ways to discover new brain-targeting
molecules that could enable delivery of drugs across the BBB and
into the CNS. A few brain shuttling molecules have been iden-
tiﬁed, including IgG antibodies55 and ligands for cell surface
receptors on the brain microvascular endothelium that help drugs
transit through the endothelium and into the CNS via receptor-
mediated transcytosis56. Accurate in vitro assessment of CNS-
targeted drug delivery has not been possible previously because
it requires that human BBB culture models provide a physiolo-
gical barrier that prevents paracellular leakage, as well as
expression of brain endothelial cell-speciﬁc receptors and trans-
porters. Given the high level of differentiation of iPS-BMVECs in
our hypoxia-induced human BBB Chip, we explored whether this
improved model can be used to directly assess the human BBB-
penetrating capacity of peptides, nanoparticles, and antibodies
in vitro.
Angiopep-2 is a small peptide ligand of LRP-1, expressed by
iPS-BMVECs (Supplementary Figure 10), that has been shown to
penetrate the BBB in vitro and in vivo57. The brain penetrating
capacity of multiple drugs, including paclitaxel58 and a cancer
therapeutic HER-2 antibody59, has been shown to be enhanced
when modiﬁed with Angiopep-2. When we ﬂowed Q-dot
nanoparticles (20 nm) coated with Angiopep-2 through the
endothelium-lined vascular channel of the human BBB Chip,
these particles exhibited. Approximately 3.5-fold greater capacity
to penetrate into the CNS channel compared with Q-dots
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coated with a scrambled peptide (Fig. 5a), even though there
was no signiﬁcant change in barrier integrity (Supplementary
Figure 11a).
The transferrin receptor (TfR) on BMVECs (Supplementary
Figure 10) also has been shown to function as a molecular
shuttle60 that can mediate differential penetration of anti-TfR
antibodies through the BBB that differ in their binding afﬁnity.
More speciﬁcally, the anti-TfR antibody MEM75 has been shown
to penetrate into the brain more efﬁciently than the 13E4
antibody in vitro61. This is because MEM75 has a reduced afﬁnity
for the receptor at pH 5.5, while the 13E4 anti-TfR antibody
exhibits a pH-independent afﬁnity that results in its entrapment
within intracellular vesicles in brain endothelial cells. In past
studies with in vitro human BBB models, including studies with
human iPS-BMVECs in Transwell cultures, it was not possible to
replicate this highly clinically relevant form of shuttling across the
BBB because of the poor barrier function and high levels of
paracellular inﬂux61,62, and we obtained similar results when
MEM75 or 13E4 antibodies were ﬂowed through the vascular
channel with the BBB Chip containing endothelium differentiated
under normoxic conditions (Fig. 5b). We also did not observe any
signiﬁcant difference in transcytosis ability between these two TfR
antibodies when we ﬂowed the antibodies through BBB Chips
lined by primary (as opposed to iPSC-derived) human BMVECs
(Supplementary Figure 12), which produced only a minimal
(~1.4-fold) difference in transcytosis abilities for the two TfR
antibodies much as previously observed in past microﬂuidic
primary BBB models63. In contrast, when these anti-TfR
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antibodies were ﬂowed through the vascular channel of the
hypoxia-enhanced BBB Chip, we were able to demonstrate
threefold higher penetrance of MEM75 into the CNS channel
relative to the 13E4 antibodies that was previously predicted
in vitro61 (Fig. 5b), and this was accomplished without
compromising general barrier integrity (Supplementary Fig-
ure 11b). In addition, BBB Chips formed with iPS-BMVECs
induced by exposure to CoCl2, exhibited similar differential
transcellular transport, again capturing the threefold difference
between the two anti-TFR antibodies (Fig. 5b) without disrupting
barrier integrity (Supplementary Figure 11c).
Discussion
Taken together, these results demonstrate that mimicking the
hypoxic microenvironment of the developing brain during dif-
ferentiation of human iPSCs into BMVECs, by either lowering
oxygen levels or adding HIF1α-inducing mimetics (e.g., CoCl2 or
DMOG), enables differentiation of endothelial cells that recapi-
tulate human-relevant physiological BBB properties when the
cells are interfaced with human brain astrocytes and pericytes in a
2-channel microﬂuidic BBB Chip. This is the ﬁrst human BBB
Chip model that permits analysis of the BBB-penetrating activ-
ities of known BBB shuttle peptides, as well as analysis of the TfR-
based antibody shuttling mechanism61, under physiologically
relevant ﬂow conditions in vitro. In addition, this enhanced BBB
Chip replicates the delivery of a clinically approved therapeutic
antibody (cetuximab) by reversible osmotic opening of the
human BBB in vitro, as is observed in human patients. Thus,
while past work in this ﬁeld described other human BBB models
that contained similar cells maintained under different culture
conditions (e.g., single channel microﬂuidic devices64, 3D tube-
like cultures6,65), none of them demonstrated these various
clinically relevant functionalities (e.g., in vivo-like barrier func-
tion for 2 weeks compared with 2–3 days in past studies) and
technical capabilities (e.g., real-time measurements of barrier
function using integrated TEER electrodes). These functional
properties are crucial for a preclinical drug development tool that
can be used for discovery of new BBB shuttles and brain-targeted
therapeutics, which was the speciﬁc focus of this study.
The human BBB Chip containing human iPS-BMVEC differ-
entiated under developmentally inspired hypoxic conditions
exhibited greatly increased and sustained barrier function than
past in vitro BBB models with TEER levels similar to those
estimated for the human BBB in vivo66. Moreover, this enhanced
induction of brain-speciﬁc endothelial cell differentiation by
hypoxia is mediated by HIF1α, and the hypoxia conditioning
step can be circumvented by artiﬁcially increasing HIF1α levels
using small molecules (CoCl2 or DMOG) that have been pre-
viously shown to mimic the effects of hypoxia under normoxic
conditions39,67.
We and others have previously developed 3D human BBB Chip
models using immortalized, primary, or iPS-derived BMVECs,
but they either fail to generate in vivo-like barrier function or
rapidly lose their phenotypic properties6,13,68,69. Another micro-
ﬂuidic BBB Chip was developed as a potential tool for drug
testing that contains human iPS-BMVECs derived under nor-
moxic conditions and cultured under continuous ﬂow35; how-
ever, those cells were interfaced with rat (rather than human)
astrocytes, there were no pericytes in that model, and active
barrier function speciﬁcally mediated by active efﬂux pumps was
not fully assessed. Another microﬂuidic BBB model was devel-
oped utilizing iPS-BMVECs that provides a tight barrier function
for up to 6 days64, but this model only contains a single micro-
ﬂuidic channel, which makes it difﬁcult to carry out TEER
measurements, explore the contributions of parenchymal cells, or
test for the transcytotic delivery of different drugs from capillary
channels to brain side. A self-organized microvascular model of
the BBB utilizing human iPS-BMVECs and human primary
astrocytes and pericytes cultured within a ﬁbrin gel has been
developed65; however, utilization of ﬁbrin gel makes it difﬁcult to
incorporate electrodes for TEER measurements to quantitatively
and continuously assess barrier function with high sensitivity, as
done in our 2-channel human BBB Chip. Diffusion of small
molecules into the ﬁbrin gel, and long residence time, also
makes it difﬁcult to accurately and quantitatively measure trans-
BBB permeability values when using ﬂuorescent tracers. The
advantage of the hypoxia-enhanced BBB Chip in which the
differentiated human brain microvascular endothelium also
experiences dynamic ﬂuid ﬂow and shear stress that signiﬁcantly
inﬂuence BBB structure and function70 is that it sustains in vivo-
like barrier functions, as well as tightly regulated transcellular
transport activities that are crucial for drug development studies,
for much longer period of time (at least 2 weeks) compared with
past human BBB models. The 2-channel design of the human
BBB Chips also enables direct and independent access to both the
parenchymal and vascular compartments, as well as real-time
TEER measurements for quantitative assessment of barrier
function, which greatly facilitates trans-BBB shuttling studies.
Hence, the human BBB Chip should provide a more accurate
model for assessing the ability of chemicals, CNS therapeutics,
and drug targeting vehicles to pass through the human BBB and
enter the brain.
The enhanced differentiation conditions we applied were
inspired by the observation that the BBB forms in a hypoxic
environment during embryological development20,22,38, and this
is accompanied by expression of Wnt7a/Wnt7b25,26, as well as
HIF1α27,28. Interestingly, when we differentiated the human
iPSCs under similar hypoxic conditions, they expressed a similar
developmental program including expression of Wnt7a and
HIF1α, indicating that hypoxia triggers these changes in vitro as
well. Importantly, this response was also accompanied by upre-
gulation of various biomarkers associated with brain neovascu-
larization including VEGF, GLUT-1, VE-cadherin, and PECAM
during the differentiation of iPS-BMVECs, as well as improved
formation of cell–cell junctions and membrane transporters that
resulted in signiﬁcantly improved BBB function that was stable
over longer times than observed in past models. But induction of
HIF1α appears to be the essential trigger for the generation of an
enhanced in vivo-like BBB Chip as similar induction of iPS-
BMVEC differentiation could be obtained by addition of small
molecule inducers of HIF1α (CoCl2 and DMOG). In fact, treat-
ment with these hypoxia mimetics may prove to be a useful
method to generate improved iPSC-derived BBB Chips without
requiring a specialized hypoxic chamber. It is also interesting to
note that this hypoxia-induced differentiation response appears
to be speciﬁc for the human iPSCs as exposure to human
primary adult BMVECs to hypoxia results in the opposite
response (e.g., increased levels of HIF1α induce expression of
VEGF, which leads to higher BBB permeability and edema)71,72.
In contrast, in the hypoxia-induced iPS-BMVECs, this response
was not observed likely because HIF1α levels decreased drastically
when the differentiated hBMVECs were seeded in the chip.
Using the hypoxia-enhanced human BBB Chip, we were able to
demonstrate that many clinically relevant responses of the BBB
can be recapitulated in vitro. The ﬁrst and most important is
maintenance of sustained levels of low barrier permeability
similar to those observed in human brain for more than 2 weeks
in vitro. We also showed that the BBB Chip can be used to
study reversible opening of the BBB using hypertonic solutions
in vitro, as is done in vivo; this technique may be used to
develop improved therapeutic delivery strategies in the future, as
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demonstrated here by delivery of an FDA approved therapeutic
antibody, mimicking a clinically relevant drug delivery strategy52.
Even more importantly, the enhanced BBB chip was able to
mimic transporter-mediated drug efﬂux including appropriate
substrate speciﬁcity. Using our enhanced BBB Chip, we ﬁrst
recapitulated in vivo interaction of P-gp and citalopram10,41
under physiological ﬂow, which could not be reproduced under
static conditions in past 3D models. Therefore, our BBB Chip
model demonstrated the advantage of using microﬂuidic system
to mimic in vivo cellular transport of molecules. Furthermore,
in vivo shuttling of CNS-targeting peptides, nanoparticles, and
antibodies across the BBB were recapitulated using enhanced BBB
Chip, enabling examination of CNS-targeting drug delivery sys-
tems as well.
In summary, the human BBB Chip created using iPS-BMVECs
exposed to developmentally inspired hypoxic differentiation
conditions and cultured under physiological ﬂow when interfaced
with human brain pericytes and astrocytes exhibits enhanced
functionalities relative to past human BBB models. These func-
tionalities provide long-term improvements resulting in forma-
tion of a stable BBB with high, in vivo-like permeability
restriction that lasts up to 2 weeks; high levels of expression of
tight junction, SLC and ABC proteins; and proper function of
efﬂux proteins, as well as drug, peptide, nanoparticle, and anti-
body transcytosis capabilities that are dependent on TfR and
LRP1 surface proteins. This enhanced human BBB Chip provides
a signiﬁcant advance as it allows for improved drug screening by
better recapitulating the in vivo environment of the BBB. It may
therefore prove useful for development of drugs or delivery
vehicles that selectively cross the BBB and target the CNS, as well
as for modeling CNS diseases in vitro using patient-derived iPSCs
to investigate improved brain therapies and advance personalized
medicine.
Methods
Cell culture. The human iPS cell line IMR90-4 (WiCell Research Institute) was
propagated on tissue-culture plate that were coated with Matrigel (BD Biosciences)
by using mTeSR1 medium (Stem Cell Technology) and maintained according
to WiCell Feeder Independent Pluripotent Stem Cell Protocols provided by the
WiCell Research Institute (http://www.wicell.org). Primary human astrocytes iso-
lated from cerebral cortex were obtained from ScienCell and maintained in
Astrocyte medium (ScienCell). Primary human brain pericytes were also obtained
from ScienCell and maintained in Pericyte medium (ScienCell). The primary cells
were used at passage 3–6.
BMVEC differentiation. Human iPS cells were differentiated to hBMVEC as
previously described33 with modiﬁcation of O2 conditions. Brieﬂy, IMR90-4 iPSCs
(WiCell Research Institute, Inc.) were dissociated using Accutase and seeded on 6-
well plate coated with Matrigel at a concentration of 1.8 × 105 cells per well. Cells
were cultured with mTeSR1 media for three days until the concentration reaches to
2.5 × 105 cells per well. The human iPSCs were differentiated to a mixed endothelial
cells and neural progenitor cell culture by switching cells to unconditioned medium
(UM) for 6 days (D0-D6). UM includes 392.5 mL DMEM/F12 (Invitrogen), 100
mL of Knockout Serum Replacement (KOSR) (Thermo Fisher Scientiﬁc), 5 mL of
non-essential amino acids (Invitrogen), 2.5 mL of Glutamax (Invitrogen), and 3.5
µL of β-mercaptoethanol (Sigma). The endothelial cells were selectively expanded
by switching to endothelial cell (EC) media supplemented with retinoic acid (RA)
(D7-D8). For steady 5% O2 conditions during the differentiation (from D0 to D9),
cells were cultured in the incubator (Heracell™ 150i Tri-Gas Incubator, Thermo
Scientiﬁc) ﬂushing with a 5% O2–5% CO2–N2 balance continuously. To analyze the
mRNA expressions during the BMVEC differentiation, total RNA was extracted
from cell culture using RNeasy Mini Kit (Promega) and cDNA was synthesized
using Maxima First Strand cDNA synthesis Kit according to the instruction’s
protocol. The multiplex qPCR was performed by using TaqMan probes (Thermo
Fisher Scientiﬁc) in a QuantStudio 7 Flex (Thermo Fisher Scientiﬁc). Label-free
proteomics were carried as described previously using mass spectrometry
analysis73.
Device fabrication. The design of the human BBB-on-a-chip was modiﬁed from
the previously reported human Small Airway Chip74. Parts for apical and basal
channels were cast in polydimethylsiloxane (PDMS) (Sylgard 184, Ellsworth
Adhesives) at a 10:1 ratio of base to curing agent in custom 3D printed Prototherm
molds (Proto Labs). The hollow microchannels were 2-cm long and 1-mm wide;
top and bottom channels were 1 and 0.2 mm high, respectively. PDMS was
degassed at −80 kPa until all bubbles were removed, and cured at 60 °C for at least
4 h. Twenty-micrometer thick, transparent, track etched, polyethylene ter-
ephthalate (PET) membranes with 0.4-µm perpendicular pores at a pore density of
4 × 106 pores cm−2, were purchased from A.R. Brown and laser cut to size and to
add ports. Membranes were bonded to PDMS using an epoxy silane method
modiﬁed from Tang and Lee75. Brieﬂy, PDMS parts and membranes were treated
with O2 plasma at 20W for 45 s, O2 gas ﬂow 50 sccm to 0.80 mbar. PDMS parts
were submerged in a 1% (3-Glycidyloxypropyl)trimethoxysilane solution (Sigma)
and membranes were submerged in a 5% (3-Aminopropyl)triethoxysilane solution
(Sigma) for 20 min at room temperature to bond silanes to the surface of the parts.
Parts were rinsed in MilliQ ﬁltered water and dried with compressed air. Parts were
aligned and bonded by hand and placed in a 60 °C oven under 500 g weights for at
least 12 h to anneal the bond. Chips were inspected for delamination, debris, or
other defects before use.
BBB reconstitution on a chip. PDMS surface of the chips were activated with oxygen
plasma treatment and the channels were coated with collagen IV (400 µgml−1) and
ﬁbronectin (100 µgml−1) overnight. Both channels of the chip were rinsed with PBS
and then with astrocyte media before seeding cells. For coculturing astrocytes and
pericytes in the brain channel of the BBB Chip, a density of 0.7 × 106 cells ml−1 of
human astrocyte and 0.3 × 106 cells ml−1 of pericyte were mixed together in the
astrocyte media and seeded on the apical channel of the chip, then incubated in the
incubator for 1 h. To remove the access of the astrocyte and pericytes, channels of the
chip were washed with EC+RA medium (endothelial medium with addition of
ﬁbroblast growth factor (Fgf) and retinoic acid (RA)33) and then 2.3 × 107 cells ml−1 of
iPS-BMVEC (D8) was seeded in the basal channel, and the device was ﬂipped
immediately to allow the BMVECs to adhere to the ECM-coated PET membrane. After
5 h incubation in the hypoxic incubator, the device was ﬂipped back to let the rest of
BMVECs sit on the bottom and sides of the channel to form a capillary lumen. Chips
seeded with cells were maintained in the hypoxic incubator for 24 h, and then the BBB
Chip was fed with EC medium deprived of Fgf and RA and transferred to the regular
incubator (5% O2–5% CO2). On the second day of cell seeding on the microﬂuidic
device, BBB Chips were attached to peristaltic pumps (microprocessor controlled
dispensing pump from Ismatec), and EC medium was ﬂowed through the channels
(60–100 µL h−1) to allow the BBB Chips adjust to ﬂow conditions; then on the third
day of seeding dosing studies were performed. For TEER measurements, we seeded
astrocyte, pericyte, and iPS-BMVEC on TEER chips32, and measured the four-point
impedance using a PGstat128N from Metrohm Autolab BV as previously reported32.
Apparent permeability (Papp) of the barrier was calculated by following a previously
described method73. Brieﬂy, 100 µgmL−1 of dextran tracers were dosed through the
vascular channels for a known period of time, and concentration of the dextran tracers
in the outlet samples from both vascular and brain channels was determined by using
BioTek (BioTek Instruments, Inc., Winooski, VT, USA). Then, following equation was
used to calculate Papp:
Papp ¼
Vr ´Cr
A ´ t ´ ðCdout ´VdþCr ´VrÞVdþVrð Þ
ð1Þ
Here, Vr is volume of receiving channel at time t, Vd is volume of dosing channel at
time t, A is area of membrane which is 0.167 cm2 in our chip model, Cr is measured
concentration of tracer in the receiving channel, and Cd-out is measured concentration
of tracer in the dosing channel efﬂuent. Furthermore, we quantiﬁed the percent loss
of the molecules into the chip materials with and without cells being present. We
tracked the inlet dosing concentrations for both vascular and brain channels as well as
outlet concentrations of both channels. Tracer loss (%) was monitored and accounted
for during the experiment using the following formula:
Tracer loss %ð Þ ¼ 100 ´ 1 Cdout ´Vdð Þ þ Cr ´Vrð Þ
Cdin ´Vd
 
ð2Þ
Here, Cd-out is the measured concentration of tracer in dosing channel efﬂuent, Cd-in is
the concentration of dosing medium in inlet, Cr is the measured concentration of tracer
in receiving channel efﬂuent. Vd is the volume of dosing channel efﬂuent at time t,
and volume of receiving channel efﬂuent at time t.
Immunoﬂuorescence microscopy. BBB Chips were ﬁxed with 4% paraf-
ormaldehyde in PBS for 10 min and then washed with PBS. Immunostaining was
performed after permeabilization in PBS with 0.1% Triton X-100 (Sigma) and
blocking for 30 min in 10% goat serum in PBS with 0.1% Triton X-100. Antibodies
used in the study were listed in the Online Reporting Summary, which were 1:100
dilutions in 10% goat serum and incubated overnight on the BBB Chip at 4 °C.
Fluorescently conjugated secondary antibodies with Alexa Fluor-488, Alexa Fluor-
555, or Alexa Fluor-647 were then used when the primary antibodies are not
conjugated. Conventional confocal imaging was carried out with a 405-laser diode,
an Argon laser and a tunable white laser using a Leica SP5 X MP Inverted Laser
Scanning Confocal Microscope with an ~25 Å water immersion objective and a
Zeiss Axio Observer microscope. For electron microscopy images, BBB chips
samples were embedded in LR white resin by following the protocol used in
Harvard Medical School Electron Microscopy Facility. Brieﬂy, the BBB Chip is
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washed in 0.1 M cacodylate buffer and post-ﬁxed with 1% osmium tetroxide
(OsO4)/1.5% potassium ferrocyanide (KFeCN6) for 1 h, washed in water for three
times and incubated in 1% aqueous uranyl acetate for 1 h followed by two washes
in water and subsequent dehydration in grades of alcohol (10 min each; 50%, 70%,
90%, 2 × 10 min 100%). The samples were incubated in a 1:1 mixture of 100%
ethanol and LR White (EMS), followed by two changes of pure LR White for 1 h
followed by overnight incubation in pure LR white. The following day, the samples
were placed in a new LR White resin in gelatin capsules (EMS) and polymerized at
60 °C for 48 h. Ultra-thin sections (about 80 nm) were cut on a Reichert Ultracut-S
microtome, picked up on copper grids, stained with lead citrate and examined in a
JEOL 1200EX Transmission electron microscope. Images were recorded with an
AMT 2k CCD camera and saved as TIFF ﬁles.
BBB opening using hypertonic solution. Hypertonic solution was generated by
mixing 20% Mannitol Injection USP (1100mOsmol L−1) and EC (280mOsmol L−1)
media in 1:3 ratio considering the dilution after intravenous or intra-arterial injection
in the body. The isotonic solution was generated by mixing PBS and EC media in 1:3
ratio. The apparent permeability (Papp) of ﬂuorescently labeled 10 kDa dextran tracer
(Thermo Fisher) and cetuximab (Selleckchem.com, USA) on BBB Chip was measured
before treating hypertonic solution and rinsed with regular EC media. To open the
barrier, the endothelial channel in the BBB Chip was fed with hypertonic solution at
100 µl h−1 ﬂow rate for 1 h (−1 to 0 h), and the media was switched to hypertonic
solution including 100 µgml−1 of 10 kDa dextran and 10 µgml−1 of cetuximab (0–1
h). After collecting the efﬂuents at 1 h, the media was switched to isotonic media with
same dose of 10 kDa dextran and cetuximab to let the barrier recover. The efﬂuent
was collected at 30min, 1.5 h, and 3.5 h after switching to isotonic media, and the Papp
of the 10 kDa dextran and cetuximab were analyzed by microplate reader and human
IgG1 ELISA kit (Sigma).
Metabolic barrier function. P-gp, MRP, and BCRP functionality were assessed
using rhodamine 123 (Sigma), DiOC2 (3,3′-diethyloxacarbocyanine Iodide)
(Sigma), citalopram (Sigma), and doxorubicin (Sigma). Both channels were pre-
treated with 50 µM verapamil (Sigma), 10 µM MK571 (Sigma), or 1 µM Ko143,
which are inhibitors of P-gp, MRPs, or BCRP, respectively. At 30 min after pre-
treatment with inhibitors, rhodamine 123 (2 µM), DiOC2 (2 µM), citalopram or
doxorubicin (5 µM) in the presence or absence of inhibitor was dosed to brain
endothelial channel with ﬂow rate at 100 µl h−1. To monitor the barrier integrity,
100 µg ml−1 of 3 kDa dextran-cascade blue (Thermo Fisher) was dosed simulta-
neously. We collected apical and basal efﬂuent for 6 h and tracers in the efﬂuents
were quantiﬁed by measuring ﬂuorescent intensity. The ﬂuorescence was measured
at 485/530 nm, 482/497 nm, or 470/585 nm to quantify rhodamine 123, DiOC2, or
doxorubicin, respectively, using a Synergy H1 microplate reader (BioTek, USA).
Amount of citalopram in the apical and basal media was quantiﬁed using mass
spectroscopy. The increase of BBB permeability of the drugs in the presence of
inhibitor was presented as ‘ratio of Papp’.
BBB transcytosis of antibodies and peptide-modiﬁed Q-dots. For the trans-
cytosis assay, 10 µg ml−1 of MEM-75 or 13E4 from Abcam (Cambridge, UK) was
ﬂowed to the brain endothelial channel at 60 µl h−1 for 3 h, and the efﬂuents were
collected for the analysis. The detection and quantiﬁcation of antibodies were
performed by ELISA as described in previous report61. Brieﬂy, 5 µg mL−1 of goat-
anti-mouse antibody (Jackson ImmunoResearch) was immobilized on a high
binding 96-well plate in carbonate buffer pH 9.5 for overnight at 4 °C. Plate was
washed with PBS with 0.1% Tween 20 for three times. 1% BSA in PBS was used to
block the plate for 1 h at RT. Antibody samples collected from BBB Chips were
incubated on the plate in the EC media for 2 h at RT. Then, an HRP-conjugated
anti-mouse secondary antibody (Jackson ImmunoResearch) was used to detect the
MEM75 and 13E4 antibodies on the plate. HRP enzyme on the secondary antibody
was quantiﬁed using a luminescent substrate (Sigma). Standard curves for MEM75
and 13E4 antibodies was generated on the same plate to calculate the concentra-
tions of the antibodies in the samples (Supplementary Figure 13). The luminescent
intensity of the plates was measured using a Synergy H1 microplate reader (BioTek,
USA), and the antibody concentrations in the samples from the brain and vascular
channels of the BBB Chip was quantiﬁed to calculate the Papp (cm s−1).
To generate the Angiopep-2 modiﬁed Q-dot, C-terminally biotinylated
Angiopep-2 (TFFYGGSRGKRNNFKTEEY) and scrambled Angiopep-2
(TGFKYRFGSKEGRNNYTEF) were purchased through the custom peptide
synthesis service of Peptide 2.0 (USA), and Qdot 655 ITK Streptavidin Conjugate
Kit was purchased from Thermo Fisher Scientiﬁc. Four micrometers of C-
terminally biotinylated synthetic Angiopep-2 or scrambled Angiopep-2 was
incubated with 0.4 µM of Q-dots for 30 min at 4 °C with agitation. The unbound
peptides were cleared by using protein desalting column, 7K MWCO (Pierce)
following instruction. Four micrometers of Angiopep-2 modiﬁed or scrambled
Angiopep-2 modiﬁed Q-dot was dosed to brain endothelial channel at 100 µl h−1
for 6 h, and the efﬂuents were collected for analysis. The ﬂuorescent intensity of
efﬂuent was measured using a Synergy H1 microplate reader (BioTek, USA) at 488/
655 nm, and the Q-dot was quantiﬁed to calculate the Papp (cm s−1).
Statistical analyses. All data represent means (± SE) of distinct sample mea-
surements (N > 2). The statistical analysis is two-way ANOVA with Tukey’s
multiple comparisons test; *P < 0.05; **P < 0.001; ***P < 0.0001. Prism 7 (GraphPad
Software) was used for statistical analysis.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published article
(and its supplementary information ﬁles), or are available from the corresponding author
upon request.
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